Slide 29 gives 109-week data for MMSE and ADCS-ADL scores for six of the 27 patients who finished part A. The data show either an increase or minimal decrease for five patients, with an initial increase, then a small decrease for the sixth. Those five patients are numbered 1009, 1011, 1014, 2006, and 2010; the sixth is 1013.
Slide 27 in the October presentation, however, shows that another five patients had small decreases, at least in the 12-week time period shown. These are numbers 1003, 1007, 1008, 1017, and 2004. The number of patients is very small, but overall, the results are very promising.
In order to maximize concentration of 2-27 in the brain, the phase 3 study might go with a titration period, so as not to lose patients early on in the process.
Today's presentation also suggests that "Alzheimer’s patients with milder disease stage (baseline MMSE >20) tended to respond better...than patients with more advanced disease stage (baseline MMSE <20)." This will be an important criterion for the phase 3 study: enroll patients having scores over 20.